Aktis Oncology, Inc. (AKTS)

Market Cap	1.18B
Revenue (ttm)	6.50M +336.9%
Net Income	-63.73M
EPS	-78.34
Shares Out	55.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	267,411
Open	21.81
Previous Close	22.08
Day's Range	21.01 - 23.05
52-Week Range	14.72 - 29.16
Beta	n/a
Analysts	Strong Buy
Price Target	31.50 (+48.17%)
Earnings Date	May 12, 2026

About AKTS

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 9, 2026
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: AKTS
• Website: https://www.aktisoncology.com

Financial Performance

In 2025, Aktis Oncology's revenue was $6.50 million, an increase of 336.92% compared to the previous year's $1.49 million. Losses were -$63.73 million, 44.9% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for AKTS stock is "Strong Buy." The 12-month stock price target is $31.5, which is an increase of 48.17% from the latest price.

Price Target

$31.5

(48.17% upside)

Analyst Consensus: Strong Buy